Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports
Anwar Khedr, Hussam Al Hennawi, Muhammed Khuzzaim Khan, Aalaa Eissa, Mikael Mir, Ibtisam Rauf, Jain Nitesh, Salim Surani, Syed Anjum Khan
Anwar Khedr, Department of Medicine, Bronx Care Health System, Bronx, NY 10457, United States
Hussam Al Hennawi, Department of Internal Medicine, Jefferson Abington Hospital, Abington, PA 19001, United States
Muhammed Khuzzaim Khan, Department of Internal Medicine, Dow University of Health Science, Karachi 74200, Pakistan
Aalaa Eissa, Department of Medicine, Kafrelsheikh University, KFS 33511, Egypt
Mikael Mir, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States
Ibtisam Rauf, Department of Medicine, St. George’s University, School of Medicine, St. George SW17 0RE, Grenada
Jain Nitesh, Department of Critical Care, Mayo Clinic Health System, Mankato, MN 56001, United States
Salim Surani, Department of Medicine & Pharmacology, Texas A&M University, College Station, TX 77843, United States
Syed Anjum Khan, Department of Critical Care Medicine, Mayo Clinic Health System, Mankato, MN 56001, United States
Author contributions: Khedr A, Hennawi HA, Khan MK, Eissa A, Mir M, and Rauf I contributed to the conception and design of the manuscript; Khan MK, Eissa A, Mir M, Rauf I and Nitesh J contributed to the collection of the data; Khedr A, Hennawi HA, Mir M, Rauf I, and Nitesh J contributed to the interpretation of the analysis; Khedr A, Hennawi HA, Khan MK, Eissa A, and Nitesh J drafted the manuscript; Surani S and Khan SA provided the oversight; All the authors critically revised the manuscript, gave final approval, and agreed to be accountable for all aspects of the work, ensuring integrity and accuracy.
Conflict-of-interest statement: None of the authors have any conflict to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Salim Surani, FCCP, MD, MHSc, Academic Editor, Professor, Department of Medicine & Pharmacology, Texas A&M University, 400 Bizzell St, College Station, TX 77843, United States.
srsurani@hotmail.com
Received: May 29, 2023
Peer-review started: May 29, 2023
First decision: June 19, 2023
Revised: July 13, 2023
Accepted: July 28, 2023
Article in press: July 28, 2023
Published online: August 26, 2023
Processing time: 87 Days and 17.5 Hours
